uniQure Reacquires Development and Commercialization Rights for its Gene Therapy Candidate in Hemophilia B – Nasdaq
|
uniQure Reacquires Development and Commercialization Rights for its Gene Therapy Candidate in Hemophilia B
Nasdaq LEXINGTON, Mass. and AMSTERDAM, the Netherlands, July 31, 2017 (GLOBE NEWSWIRE) — uniQure N.V. (NASDAQ:QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced … |
